金融毒性综合评分（COST）的重新验证：评估该量表在慢性病患者群体中的效用。
Re-Validation of the COmprehensive Score for Financial Toxicity (COST): Assessing the Scale's Utility in Chronic Disease Populations.
作者信息
Pavela G, Fifolt M, Tison S E, Allison M, Burton B S, Ford E W
机构信息
Department of Health Behavior, School of Public Health, University of Alabama at Birmingham, Birmingham, AL, USA.
Department of Health Care Organization, and Policy, School of Public Health, University of Alabama at Birmingham, Birmingham, AL, USA.
出版信息
Health Serv Insights. 2021 Dec 10;14:11786329211057352. doi: 10.1177/11786329211057352. eCollection 2021.
OBJECTIVE
To report the psychometric properties of the COmprehensive Score for financial Toxicity (COST) patient-reported outcome measure (PROM), an 11-item scale previously validated among patients diagnosed with cancer and receiving chemotherapy.
METHODS
Data come from a cross-sectional survey (n = 2755 response rate of 87%) of participants in a remote digital health coaching intervention collected between January 2017 and February 2019.
RESULTS
COST demonstrated very good internal consistency ( = .89) and good convergent validity. Lower financial toxicity was associated with improved physical and mental well-being HRQOL measures after controlling for covariates ( = 0.13, < .0001; = 0.28, < .0001, respectively). Supplemental analyses indicated that the COST instrument loaded on 2 factors.
CONCLUSIONS
The COST measure of financial toxicity has good internal consistency and predictive validity in a sample of patients with chronic conditions. However, contrary to previous research examining the psychometric properties of COST in a sample of individuals with cancer, which found COST to be unidimensional, our analyses indicated that the COST measure of financial toxicity is multidimensional in a sample of individuals with chronic conditions. In particular, the items that asked about "general financial wellbeing" loaded on the second factor while "illness-related financial wellbeing" loaded on the first.
目的
报告财务毒性综合评分（COST）患者报告结局量表（PROM）的心理测量学特性，这是一个由11个项目组成的量表，先前已在被诊断患有癌症并接受化疗的患者中得到验证。
方法
数据来自于2017年1月至2019年2月期间收集的一项针对远程数字健康指导干预参与者的横断面调查（n = 2755，应答率为87%）。
结果
COST显示出非常好的内部一致性（= 0.89）和良好的收敛效度。在控制协变量后，较低的财务毒性与改善的身心健康HRQOL指标相关（分别为 = 0.13，< 0.0001； = 0.28，< 0.0001）。补充分析表明，COST工具加载在两个因素上。
结论
财务毒性的COST测量在慢性病患者样本中具有良好的内部一致性和预测效度。然而，与先前在癌症患者样本中研究COST心理测量学特性的研究不同，先前研究发现COST是单维的，我们的分析表明，在慢性病患者样本中，财务毒性的COST测量是多维的。特别是，询问“一般财务状况”的项目加载在第二个因素上，而“与疾病相关的财务状况”加载在第一个因素上。
Zotero 插件